Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
222
-
Total 13F shares, excl. options
-
156M
-
Shares change
-
+8.15M
-
Total reported value, excl. options
-
$1.79B
-
Value change
-
+$88.2M
-
Put/Call ratio
-
0.38
-
Number of buys
-
121
-
Number of sells
-
-85
-
Price
-
$11.48
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2022
273 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q4 2022.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 222 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 156M shares
of 210M outstanding shares and own 74.56% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14.9M shares), VANGUARD GROUP INC (14.2M shares), BAKER BROS. ADVISORS LP (12.7M shares), STATE STREET CORP (11.1M shares), Avoro Capital Advisors LLC (9.05M shares), FMR LLC (7.12M shares), PICTET ASSET MANAGEMENT SA (5.29M shares), Fisher Asset Management, LLC (4.43M shares), RP Management, LLC (3.85M shares), and GEODE CAPITAL MANAGEMENT, LLC (3.47M shares).
This table shows the top 222 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.